• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia.ERG 和 FLI1 结合位点标志着 AML1-ETO 在急性髓系白血病中异常表观遗传调控的靶标。
Blood. 2012 Nov 8;120(19):4038-48. doi: 10.1182/blood-2012-05-429050. Epub 2012 Sep 14.
2
The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs.造血转录因子RUNX1和ERG可防止t(8;21)急性髓系白血病(AML)中AML1-ETO致癌基因的过度表达及凋亡程序的启动。
Cell Rep. 2016 Nov 15;17(8):2087-2100. doi: 10.1016/j.celrep.2016.08.082.
3
Chromatin modifications induced by the AML1-ETO fusion protein reversibly silence its genomic targets through AML1 and Sp1 binding motifs.AML1-ETO 融合蛋白诱导的染色质修饰通过 AML1 和 Sp1 结合基序可逆性地沉默其基因组靶标。
Leukemia. 2012 Jun;26(6):1329-37. doi: 10.1038/leu.2011.376. Epub 2012 Jan 13.
4
Chromatin accessibility, p300, and histone acetylation define PML-RARα and AML1-ETO binding sites in acute myeloid leukemia.染色质可及性、p300 和组蛋白乙酰化定义了急性髓系白血病中 PML-RARα 和 AML1-ETO 的结合位点。
Blood. 2012 Oct 11;120(15):3058-68. doi: 10.1182/blood-2011-10-386086. Epub 2012 Aug 24.
5
Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding.t(8;21)AML 细胞中 RUNX1/ETO 的耗竭导致染色质结构和转录因子结合的全基因组变化。
Leukemia. 2012 Aug;26(8):1829-41. doi: 10.1038/leu.2012.49. Epub 2012 Feb 20.
6
Definition of a small core transcriptional circuit regulated by AML1-ETO.AML1-ETO 调控的小核心转录回路的定义。
Mol Cell. 2021 Feb 4;81(3):530-545.e5. doi: 10.1016/j.molcel.2020.12.005. Epub 2020 Dec 30.
7
The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia.在t(8;21)髓系白血病中,髓系主要调节转录因子PU.1被AML1-ETO失活。
Blood. 2003 Jan 1;101(1):270-7. doi: 10.1182/blood-2002-04-1288. Epub 2002 Aug 29.
8
AML associated oncofusion proteins PML-RARA, AML1-ETO and CBFB-MYH11 target RUNX/ETS-factor binding sites to modulate H3ac levels and drive leukemogenesis.与急性髓系白血病(AML)相关的致癌融合蛋白PML-RARA、AML1-ETO和CBFB-MYH11靶向RUNX/ETS因子结合位点,以调节H3ac水平并驱动白血病发生。
Oncotarget. 2017 Feb 21;8(8):12855-12865. doi: 10.18632/oncotarget.14150.
9
The oncofusion protein FUS-ERG targets key hematopoietic regulators and modulates the all-trans retinoic acid signaling pathway in t(16;21) acute myeloid leukemia.致癌融合蛋白FUS-ERG靶向关键造血调节因子并调节t(16;21)急性髓系白血病中的全反式维甲酸信号通路。
Oncogene. 2016 Apr 14;35(15):1965-76. doi: 10.1038/onc.2015.261. Epub 2015 Jul 6.
10
Genome-wide studies identify a novel interplay between AML1 and AML1/ETO in t(8;21) acute myeloid leukemia.全基因组研究鉴定出 t(8;21) 急性髓系白血病中 AML1 和 AML1/ETO 之间的新型相互作用。
Blood. 2016 Jan 14;127(2):233-42. doi: 10.1182/blood-2015-03-626671. Epub 2015 Nov 6.

引用本文的文献

1
Understanding blood development and leukemia using sequencing-based technologies and human cell systems.利用基于测序的技术和人类细胞系统来理解血液发育和白血病。
Front Mol Biosci. 2023 Oct 10;10:1266697. doi: 10.3389/fmolb.2023.1266697. eCollection 2023.
2
SCN4B inhibits the progression of lung adenocarcinoma and is associated with better prognosis.SCN4B 抑制肺腺癌的进展,并与更好的预后相关。
Clin Respir J. 2023 Dec;17(12):1233-1245. doi: 10.1111/crj.13709. Epub 2023 Oct 12.
3
RUNX1/ETO regulates reactive oxygen species (ROS) levels in t(8,21) acute myeloid leukaemia via FLT3 and RAC1.RUNX1/ETO 通过 FLT3 和 RAC1 调节 t(8,21) 急性髓系白血病中的活性氧(ROS)水平。
Med Oncol. 2023 Jun 21;40(7):208. doi: 10.1007/s12032-023-02075-w.
4
A RUNX1/ETO-SKP2-CDKN1B axis regulates expression of telomerase in t (8;21) acute myeloid leukemia.RUNX1/ETO-SKP2-CDKN1B 轴调节 t(8;21) 急性髓系白血病中端粒酶的表达。
Cell Mol Life Sci. 2023 Feb 23;80(3):70. doi: 10.1007/s00018-023-04713-y.
5
EVI1 exerts distinct roles in AML via ERG and cyclin D1 promoting a chemoresistant and immune-suppressive environment.EVI1 通过 ERG 和 cyclin D1 在 AML 中发挥独特作用,促进了耐药和免疫抑制的环境。
Blood Adv. 2023 Apr 25;7(8):1577-1593. doi: 10.1182/bloodadvances.2022008018.
6
A direct comparison between AML1-ETO and ETO2-GLIS2 leukemia fusion proteins reveals context-dependent binding and regulation of target genes and opposite functions in cell differentiation.AML1-ETO与ETO2-GLIS2白血病融合蛋白之间的直接比较揭示了靶基因的上下文依赖性结合与调控以及在细胞分化中的相反功能。
Front Cell Dev Biol. 2022 Sep 7;10:992714. doi: 10.3389/fcell.2022.992714. eCollection 2022.
7
Elucidating the importance and regulation of key enhancers for human MEIS1 expression.阐明关键增强子对人 MEIS1 表达的重要性和调控作用。
Leukemia. 2022 Aug;36(8):1980-1989. doi: 10.1038/s41375-022-01602-4. Epub 2022 May 27.
8
PGC1 alpha coactivates ERG fusion to drive antioxidant target genes under metabolic stress.PGC1α 协同 ERG 融合在代谢应激下驱动抗氧化靶基因。
Commun Biol. 2022 May 4;5(1):416. doi: 10.1038/s42003-022-03385-x.
9
Pioneer transcription factors are associated with the modulation of DNA methylation patterns across cancers.先驱转录因子与癌症中 DNA 甲基化模式的调节有关。
Epigenetics Chromatin. 2022 Apr 19;15(1):13. doi: 10.1186/s13072-022-00444-9.
10
KDM4B promotes acute myeloid leukemia associated with AML1-ETO by regulating chromatin accessibility.KDM4B通过调节染色质可及性促进与AML1-ETO相关的急性髓系白血病。
FASEB Bioadv. 2021 Sep 12;3(12):1020-1033. doi: 10.1096/fba.2021-00030. eCollection 2021 Dec.

本文引用的文献

1
Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding.t(8;21)AML 细胞中 RUNX1/ETO 的耗竭导致染色质结构和转录因子结合的全基因组变化。
Leukemia. 2012 Aug;26(8):1829-41. doi: 10.1038/leu.2012.49. Epub 2012 Feb 20.
2
Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets.尤因肉瘤的分子发病机制:新的治疗和转录靶点。
Annu Rev Pathol. 2012;7:145-59. doi: 10.1146/annurev-pathol-011110-130237. Epub 2011 Sep 19.
3
Abnormal expression of FLI1 protein is an adverse prognostic factor in acute myeloid leukemia.FLI1 蛋白的异常表达是急性髓系白血病的一个不良预后因素。
Blood. 2011 Nov 17;118(20):5604-12. doi: 10.1182/blood-2011-04-348052. Epub 2011 Sep 13.
4
The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation.AML1-ETO 的白血病发生能力依赖于特定位点的赖氨酸乙酰化。
Science. 2011 Aug 5;333(6043):765-9. doi: 10.1126/science.1201662. Epub 2011 Jul 14.
5
Acute myeloid leukemia: a central role for the ETS factor ERG.急性髓细胞白血病:ETS 因子 ERG 的核心作用。
Int J Biochem Cell Biol. 2011 Oct;43(10):1413-6. doi: 10.1016/j.biocel.2011.05.014. Epub 2011 Jun 1.
6
Genome-wide analysis of simultaneous GATA1/2, RUNX1, FLI1, and SCL binding in megakaryocytes identifies hematopoietic regulators.全基因组分析巨核细胞中 GATA1/2、RUNX1、FLI1 和 SCL 的同时结合,鉴定造血调控因子。
Dev Cell. 2011 May 17;20(5):597-609. doi: 10.1016/j.devcel.2011.04.008.
7
Promotion and maintenance of leukemia by ERG.ERG 促进和维持白血病。
Blood. 2011 Apr 7;117(14):3858-68. doi: 10.1182/blood-2010-11-320515. Epub 2011 Feb 14.
8
Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes.化学生物学蛋白质组学分析组蛋白去乙酰化酶抑制剂揭示了对 HDAC 复合物的选择性靶向。
Nat Biotechnol. 2011 Mar;29(3):255-65. doi: 10.1038/nbt.1759. Epub 2011 Jan 23.
9
ERG dependence distinguishes developmental control of hematopoietic stem cell maintenance from hematopoietic specification.ERG 依赖性将造血干细胞维持的发育控制与造血特化区分开来。
Genes Dev. 2011 Feb 1;25(3):251-62. doi: 10.1101/gad.2009211. Epub 2011 Jan 18.
10
Genome-wide screen reveals WNT11, a non-canonical WNT gene, as a direct target of ETS transcription factor ERG.全基因组筛选揭示 WNT11,一种非经典的 WNT 基因,是 ETS 转录因子 ERG 的直接靶标。
Oncogene. 2011 Apr 28;30(17):2044-56. doi: 10.1038/onc.2010.582. Epub 2011 Jan 17.

ERG 和 FLI1 结合位点标志着 AML1-ETO 在急性髓系白血病中异常表观遗传调控的靶标。

ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia.

机构信息

Radboud University, Department of Molecular Biology, Faculty of Science, Nijmegen Centre for Molecular Life Sciences, Nijmegen, The Netherlands.

出版信息

Blood. 2012 Nov 8;120(19):4038-48. doi: 10.1182/blood-2012-05-429050. Epub 2012 Sep 14.

DOI:10.1182/blood-2012-05-429050
PMID:22983443
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3496958/
Abstract

ERG and FLI1 are closely related members of the ETS family of transcription factors and have been identified as essential factors for the function and maintenance of normal hematopoietic stem cells. Here genome-wide analysis revealed that both ERG and FLI1 occupy similar genomic regions as AML1-ETO in t(8;21) AMLs and identified ERG/FLI1 as proteins that facilitate binding of oncofusion protein complexes. In addition, we demonstrate that ERG and FLI1 bind the RUNX1 promoter and that shRNA-mediated silencing of ERG leads to reduced expression of RUNX1 and AML1-ETO, consistent with a role of ERG in transcriptional activation of these proteins. Finally, we identify H3 acetylation as the epigenetic mark preferentially associated with ETS factor binding. This intimate connection between ERG/FLI1 binding and H3 acetylation implies that one of the molecular strategies of oncofusion proteins, such as AML1-ETO and PML-RAR-α, involves the targeting of histone deacetylase activities to ERG/FLI1 bound hematopoietic regulatory sites. Together, these results highlight the dual importance of ETS factors in t(8;21) leukemogenesis, both as transcriptional regulators of the oncofusion protein itself as well as proteins that facilitate AML1-ETO binding.

摘要

ERG 和 FLI1 是 ETS 转录因子家族的密切相关成员,被认为是正常造血干细胞功能和维持所必需的因素。在这里,全基因组分析表明,ERG 和 FLI1 都占据了 t(8;21)AML 中 AML1-ETO 的类似基因组区域,并确定 ERG/FLI1 是促进癌融合蛋白复合物结合的蛋白质。此外,我们证明 ERG 和 FLI1 结合 RUNX1 启动子,并且 shRNA 介导的 ERG 沉默导致 RUNX1 和 AML1-ETO 的表达减少,这与 ERG 在这些蛋白的转录激活中的作用一致。最后,我们确定 H3 乙酰化为与 ETS 因子结合优先相关的表观遗传标记。ERG/FLI1 结合与 H3 乙酰化之间的这种密切联系表明,癌融合蛋白(如 AML1-ETO 和 PML-RAR-α)的一种分子策略涉及将组蛋白去乙酰化酶活性靶向 ERG/FLI1 结合的造血调节位点。总之,这些结果突出了 ETS 因子在 t(8;21)白血病发生中的双重重要性,既是癌融合蛋白本身的转录调节剂,也是促进 AML1-ETO 结合的蛋白质。